135 related articles for article (PubMed ID: 37302275)
1. Low MST1/2 and negative LATS1/2 expressions are associated with poor prognosis of colorectal cancers.
Jung J; Kim JW; Kim G; Kim JY
Pathol Res Pract; 2023 Aug; 248():154608. PubMed ID: 37302275
[TBL] [Abstract][Full Text] [Related]
2. Radix Scrophulariae Extracts Exert Effect on Hyperthyroidism via MST1/Hippo Signaling Pathway.
Zhang N; Ye T; Lu X; Li ZH; Li L
Chin J Integr Med; 2023 Nov; 29(11):998-1006. PubMed ID: 37661231
[TBL] [Abstract][Full Text] [Related]
3. High Yes-associated protein 1 with concomitant negative LATS1/2 expression is associated with poor prognosis of advanced gastric cancer.
Kim E; Ahn B; Oh H; Lee YJ; Lee JH; Lee Y; Kim CH; Chae YS; Kim JY
Pathology; 2019 Apr; 51(3):261-267. PubMed ID: 30819540
[TBL] [Abstract][Full Text] [Related]
4. WWC proteins mediate LATS1/2 activation by Hippo kinases and imply a tumor suppression strategy.
Qi S; Zhu Y; Liu X; Li P; Wang Y; Zeng Y; Yu A; Wang Y; Sha Z; Zhong Z; Zhu R; Yuan H; Ye D; Huang S; Ling C; Xu Y; Zhou D; Zhang L; Yu FX
Mol Cell; 2022 May; 82(10):1850-1864.e7. PubMed ID: 35429439
[TBL] [Abstract][Full Text] [Related]
5. MAP4K family kinases act in parallel to MST1/2 to activate LATS1/2 in the Hippo pathway.
Meng Z; Moroishi T; Mottier-Pavie V; Plouffe SW; Hansen CG; Hong AW; Park HW; Mo JS; Lu W; Lu S; Flores F; Yu FX; Halder G; Guan KL
Nat Commun; 2015 Oct; 6():8357. PubMed ID: 26437443
[TBL] [Abstract][Full Text] [Related]
6. Angiomotins stimulate LATS kinase autophosphorylation and act as scaffolds that promote Hippo signaling.
Mana-Capelli S; McCollum D
J Biol Chem; 2018 Nov; 293(47):18230-18241. PubMed ID: 30266805
[TBL] [Abstract][Full Text] [Related]
7. Interaction of S100A1 with LATS1 promotes cell growth through regulation of the Hippo pathway in hepatocellular carcinoma.
Guo Q; Wang J; Cao Z; Tang Y; Feng C; Huang F
Int J Oncol; 2018 Aug; 53(2):592-602. PubMed ID: 29901195
[TBL] [Abstract][Full Text] [Related]
8. Prognostic significance of mammalian sterile20-like kinase 1 in colorectal cancer.
Minoo P; Zlobec I; Baker K; Tornillo L; Terracciano L; Jass JR; Lugli A
Mod Pathol; 2007 Mar; 20(3):331-8. PubMed ID: 17277767
[TBL] [Abstract][Full Text] [Related]
9. Effects of the hippo signaling pathway in human gastric cancer.
Zhou GX; Li XY; Zhang Q; Zhao K; Zhang CP; Xue CH; Yang K; Tian ZB
Asian Pac J Cancer Prev; 2013; 14(9):5199-205. PubMed ID: 24175801
[TBL] [Abstract][Full Text] [Related]
10. Hippo Signaling Pathway in Gliomas.
Masliantsev K; Karayan-Tapon L; Guichet PO
Cells; 2021 Jan; 10(1):. PubMed ID: 33477668
[TBL] [Abstract][Full Text] [Related]
11. The Hippo kinases control inflammatory Hippo signaling and restrict bacterial infection in phagocytes.
St Louis BM; Quagliato SM; Su Y-T; Dyson G; Lee P-C
mBio; 2024 May; 15(5):e0342923. PubMed ID: 38624208
[TBL] [Abstract][Full Text] [Related]
12. The mammalian Hippo pathway: regulation and function of YAP1 and TAZ.
Kodaka M; Hata Y
Cell Mol Life Sci; 2015 Jan; 72(2):285-306. PubMed ID: 25266986
[TBL] [Abstract][Full Text] [Related]
13. Integrin α2β1 inhibits MST1 kinase phosphorylation and activates Yes-associated protein oncogenic signaling in hepatocellular carcinoma.
Wong KF; Liu AM; Hong W; Xu Z; Luk JM
Oncotarget; 2016 Nov; 7(47):77683-77695. PubMed ID: 27765911
[TBL] [Abstract][Full Text] [Related]
14. DLG5 connects cell polarity and Hippo signaling protein networks by linking PAR-1 with MST1/2.
Kwan J; Sczaniecka A; Heidary Arash E; Nguyen L; Chen CC; Ratkovic S; Klezovitch O; Attisano L; McNeill H; Emili A; Vasioukhin V
Genes Dev; 2016 Dec; 30(24):2696-2709. PubMed ID: 28087714
[TBL] [Abstract][Full Text] [Related]
15. Transmembrane protein KIRREL1 regulates Hippo signaling via a feedback loop and represents a therapeutic target in YAP/TAZ-active cancers.
Gu Y; Wang Y; Sha Z; He C; Zhu Y; Li J; Yu A; Zhong Z; Wang X; Sun Y; Lan F; Yu FX
Cell Rep; 2022 Aug; 40(9):111296. PubMed ID: 36044856
[TBL] [Abstract][Full Text] [Related]
16. T851I mutation of human large tumor suppressor 1 disrupts its kinase activity and tumor-suppressor functions.
Zhang Q; Du X; He Q; Shi W; Mei L; Qv M; Tan D; Wu J; Zeng LH; Wu X
Life Sci; 2021 Jan; 264():118655. PubMed ID: 33141042
[TBL] [Abstract][Full Text] [Related]
17. Expression of phosphorylated Hippo pathway kinases (MST1/2 and LATS1/2) in HER2-positive and triple-negative breast cancer patients treated with neoadjuvant therapy.
Ercolani C; Di Benedetto A; Terrenato I; Pizzuti L; Di Lauro L; Sergi D; Sperati F; Buglioni S; Ramieri MT; Mentuccia L; Gamucci T; Perracchio L; Pescarmona E; Mottolese M; Barba M; Vici P; De Maria R; Maugeri-Saccà M
Cancer Biol Ther; 2017 May; 18(5):339-346. PubMed ID: 28387539
[TBL] [Abstract][Full Text] [Related]
18. MST1 inhibits the progression of breast cancer by regulating the Hippo signaling pathway and may serve as a prognostic biomarker.
Jin X; Zhu L; Xiao S; Cui Z; Tang J; Yu J; Xie M
Mol Med Rep; 2021 May; 23(5):. PubMed ID: 33760220
[TBL] [Abstract][Full Text] [Related]
19. A breakdown of the Hippo pathway in gastric cancer.
Xu ZP; Zhu JS; Zhang Q; Wang XY
Hepatogastroenterology; 2011; 58(110-111):1611-7. PubMed ID: 21940329
[TBL] [Abstract][Full Text] [Related]
20. ADAM Metallopeptidase Domain 12 Facilitates Colorectal Cancer Progression by Inhibiting Hippo Signaling Pathway Activity.
Wang X; Zhu M; Zuo H; Hou G; Xie R
Mol Cancer Res; 2023 Jun; 21(6):525-534. PubMed ID: 36806444
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
